Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Uprosertib in Relapsed/Refractory Multiple Myeloma
NCT01989598Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2013
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib and uprosertib in multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate. Started Oct 2013; status: completed.
02
Drugs
trametinibuprosertib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01989598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01989598.